Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7269063 | 0.85 | — | — | |
| SCHEMBL21910466 | 0.85 | — | — | |
| SCHEMBL7185667 | 0.83 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18685786 | 0.82 | — | — | |
| SCHEMBL1803509 | 0.82 | — | — | |
| SCHEMBL16689092 | 0.79 | — | — | |
| SCHEMBL23132260 | 0.79 | — | — | |
| SCHEMBL15095887 | 0.79 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12700286 | 0.79 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12918801 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275993-A1 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-04 | — | — | US | disclosed |
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-08-14 | — | — | US | disclosed |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-03 | — | — | US | disclosed |
| US-12312362-B2 | Spiro derivatives of Alpha-D-galactopyranosides | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-27 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-11777142-B2 | Gelable system containing ether compounds, preparation method therefor and use thereof | BEIJING NORMAL UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11777142-B2 | Gelable system containing ether compounds, preparation method therefor and use thereof | BEIJING NORMAL UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230295182-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-08 | — | — | US | disclosed |
| EP-3637524-A1 | GELATINIZED SYSTEM AND APPLICATIONS IN LITHIUM AIR BATTERY, SUPER CAPACITOR OR CAPACITOR BATTERY IN ORGANIC SYSTEM | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | disclosed |
| EP-3637525-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | disclosed |
| US-20200099096-A1 | Gelable System Containing Ether Compounds, Preparation Method Therefor and Use Thereof | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | disclosed |
| US-20200099090-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | disclosed |
| US-7871539-B2 | Liquid crystal composition, liquid crystal element, reflective display material, light-controlling material, and method of preparing liquid crystal composition | FUJIFILM CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7871539-B2 | Liquid crystal composition, liquid crystal element, reflective display material, light-controlling material, and method of preparing liquid crystal composition | FUJIFILM CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20080292817-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, REFLECTIVE DISPLAY MATERIAL, LIGHT-CONTROLLING MATERIAL, AND METHOD OF PREPARING LIQUID CRYSTAL COMPOSITION | FUJIFILM CORPORATON (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080292817-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, REFLECTIVE DISPLAY MATERIAL, LIGHT-CONTROLLING MATERIAL, AND METHOD OF PREPARING LIQUID CRYSTAL COMPOSITION | FUJIFILM CORPORATON (JP) | 2008-11-27 | — | — | US | disclosed |
| EP-1092721-A1 | Chiral glucosides and their use as chiral dopants for the production of cholesteric liquid crystalline compositions | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | CHRM2 772/4885CHRM4 1978/4885CHRM5 1325/4885 |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | CHRM2 807/4885CHRM4 1837/4885CHRM5 1565/4885 |
| US-12312362-B2 | Spiro derivatives of Alpha-D-galactopyranosides | LGALS1, LGALS3, LGALS2 | CHRM2 1679/4885CHRM4 2551/4885CHRM5 2496/4885 |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | CHRM2 807/4885CHRM4 1837/4885CHRM5 1565/4885 |
| US-20230295182-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | LGALS1, LGALS3, LGALS2 | CHRM2 1679/4885CHRM4 2551/4885CHRM5 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.